«Le opzioni terapeutiche di cui disponiamo, incluse le più recenti, nonostante la loro indiscutibile efficacia, lasciano aperti numerosi problemi: sono attive principalmente contro i genotipi 1 e 4 di HCV, e molto meno efficaci per circa un terzo dei pazienti, quelli con genotipo 2 e 3, e non danno risposte soddisfacenti in presenza di cirrosi compensata e scompensata.

An all-oral regimen of
grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without
ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates
for treatment-naive and treatment-experienced people with genotype 1 hepatitis
C virus (HCV), including people with liver cirrhosis and HIV and HCV co-infection,
researchers reported on Tuesday at
the American Association for the

Sofosbuvir/ledipasvir without
ribavirin and AbbVie’s 3D regimen (paritaprevir/ombitasvir plus dasabuvir) both
produced high sustained virological response rates for people with hepatitis C
virus (HCV) genotype 4, according to a pair of studies presented at the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting this week in Boston, USA.
HCV genotype 4, the
most

A large French study has shown that the vast
majority of people living with HIV who started treatment since 2000 in a
national cohort achieved a CD4 cell count in the normal range within three to
four years of starting treatment, while a large Italian study showed that
achieving a normal CD4 count on

An oral regimen of
sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C
patients with decompensated cirrhosis, the most advanced stage of liver
disease, according to a presentation on Tuesday at the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting in Boston.
Over years or decades,
chronic hepatitis C virus (HCV)

People with HIV – most of whom had hepatitis B
or C co-infection – generally had good outcomes after liver transplantation due
to hepatocellular carcinoma (HCC), with five-year survival rates similar to
those of HIV-negative transplant recipients and better than those of people who
underwent other types of liver cancer treatment, researchers reported this

One of the key strategies involved in trying to bring an end
to the HIV epidemic is to increase the proportion of HIV-positive people on antiretroviral
therapy (ART), to the point where suppressing their viral load starts to reduce
onward infection.
What is usually called ‘treatment as prevention’ lies behind
the
ambitious new target announced

Young people who inject drugs (PWID) who undergo opioid
agonist maintenance therapy with methadone or buprenorphine have more than a
60% reduced risk of acquiring hepatitis C virus (HCV) over time
compared to those with no substance use treatment, according to a study presented Monday at the American Association for the Study
of Liver

There was widespread misunderstanding and misinterpretation of questions
about anal sex being asked of participants inthe Vaginal
and Oral Interventions to Control the Epidemic (VOICE) trial existed, according to findings of a qualitative
ancillary study to the VOICE trial qualitative
analysis study (called MTN-003D or VOICE-D) presented at the HIV Research for Prevention conference

Treatment with a triple
antiretroviral combination containing once-daily integrase inhibitor dolutegravir
(Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir
(Prezista) over 96 weeks of follow up,Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported at the Internatinal Congress of
Drug Therapy in HIV Infection in Glasgow last week.

Dolutegravir is also a component of